Categories & Effectiveness

Brain Health

Acetylcholine Support

9/10

Strong evidence of effectiveness

Neuro-Repair Support

5/10

Moderate evidence of effectiveness

Brain Antioxidant Shield

3/10

Limited evidence of effectiveness

Cognition

Memory & Recall

6/10

Moderate evidence of effectiveness

Mental Acuity

6/10

Moderate evidence of effectiveness

Systemic Health

Cellular Anti-Aging

3/10

Limited evidence of effectiveness

Dosage & Side Effects

Recommended Dosage

The typical dosage range studied for cognitive effects in adults is 300-500 micrograms (mcg) daily, often split into two doses (e.g., 200 mcg twice daily). While lower doses (e.g., 200 mcg total daily) may be ineffective, doses up to 400 mcg twice daily (800 mcg total) have been tested and generally well-tolerated in specific trials, representing a potential upper limit explored in research. Studies often involve individuals with mild to moderate Alzheimer's disease or vascular dementia, and optimal dosing may vary based on individual factors and intended use.

Potential Side Effects

Common mild side effects are often related to increased acetylcholine levels and can include nausea, dizziness, headache, or stomachache. While generally well-tolerated in studies at typical doses, higher doses might increase the risk or severity of these cholinergic side effects, though serious adverse events have been rare in clinical trials. Individuals taking other acetylcholinesterase inhibitors (like donepezil or rivastigmine) or medications with anticholinergic effects should use caution, as should those with certain heart conditions or seizure disorders.

Bioavailability & Half-Life

Huperzine A demonstrates good penetration across the blood-brain barrier and relatively high oral bioavailability compared to some other acetylcholinesterase inhibitors. After taking it by mouth, plasma concentrations typically peak in about 60 minutes. Its action is considered reversible and selective, with a relatively long duration of effect despite having a reported elimination half-life (T½) of approximately 4 hours in humans.

Interactions & Stacks

Huperzine A is often considered for stacks aimed at boosting acetylcholine levels, potentially synergizing with choline sources like Alpha-GPC or Citicoline. Caution is advised when combining Huperzine A with other acetylcholinesterase inhibitors (prescription or supplemental) due to the risk of excessive cholinergic activity, and interactions with anticholinergic drugs are also possible. While user reports vary, research suggests it doesn't significantly alter the pharmacokinetics of cocaine but may reduce its subjective effects at specific doses.

Benefits by Use Case

Memory Support (esp. Age-Related)

May improve aspects of memory and learning by increasing acetylcholine. Evidence is strongest in populations with existing cognitive decline like Alzheimer's; effects in healthy individuals are less studied.

Alzheimer's/Dementia Adjunct

Multiple studies and meta-analyses suggest benefits for cognitive scores (MMSE, ADAS-Cog) and daily living activities in AD/VaD patients, though study quality varies. It is used clinically for AD in China but is not an FDA-approved drug elsewhere.

Focus & Attention

By boosting acetylcholine, it might indirectly support attention, but evidence for this specific use case is less robust than for memory. Effects are temporary, linked to the drug's presence in the body.

Mechanism of Action

Huperzine A primarily acts as a potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine (ACh). By inhibiting AChE, particularly the G4 form prevalent at synapses, Huperzine A increases the concentration and duration of action of ACh in the synaptic cleft, enhancing cholinergic neurotransmission, which is crucial for memory formation and recall. Beyond AChE inhibition, studies suggest Huperzine A may also act as an NMDA receptor antagonist (potentially offering neuroprotection against glutamate excitotoxicity), modulate amyloid precursor protein (APP) processing towards non-amyloidogenic pathways, protect mitochondria, reduce neuroinflammation, and potentially influence norepinephrine and dopamine levels in certain brain regions.

Frequently Asked Questions

Is Huperzine A addictive?

When is the best time to take Huperzine A?

Can I take Huperzine A every day?

Is Huperzine A safe?

Does Huperzine A really improve memory?

Can Huperzine A be stacked with other nootropics?

How quickly does Huperzine A work?

Summary & Expert Opinion

Overall, Huperzine A is a well-studied acetylcholinesterase inhibitor with compelling evidence supporting its use for cognitive enhancement, particularly memory, in populations experiencing age-related decline or dementia. Its strengths include good bioavailability, brain penetration, and a relatively favorable side effect profile at studied doses, though evidence in healthy young individuals is less robust and some clinical trial methodologies have limitations. Huperzine A may be beneficial for individuals seeking memory support, especially those with diagnosed cognitive impairment like mild-to-moderate Alzheimer's, potentially as an adjunct therapy. However, individuals taking other cholinergic or anticholinergic medications, or those with specific health conditions (like certain heart issues or epilepsy), should consult a healthcare professional before use.

Research Studies

Showing 5 of 10 studies

Natural products: Potential therapeutic agents to prevent skeletal muscle atrophy (2022)

Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease (2021)

acetylcholinesterase inhibition amyloid-beta reduction cognitive improvement +3 more

Authors:

María Jesús Friedli

Findings:

Huperzine A (HupA), an acetylcholinesterase inhibitor (AChEI) from Huperzia serrata, shows neuroprotective effects relevant to Alzheimer's Disease (AD) through various molecular signaling pathways. Studies indicate HupA reduces amyloid-β (Aβ) accumulation by modulating APP processing (promoting α-secretase, reducing BACE1), interacts with Wnt signaling, protects mitochondria from Aβ-induced dysfunction, reduces neuroinflammation (cytokine release, NF-kB signaling), and may regulate iron homeostasis. Clinical trials suggest HupA improves cognitive function in AD and VaD patients in a dose- and duration-dependent manner with generally mild side effects.

Participants:

In vitro (primary cortical neuron cultures, co-culture of neural stem cells and microglia, primary astrocyte cultures), in vivo (APPswe/PS1 double transgenic mice, TgCRND8 mice, wild-type mice), and human studies (patients with Alzheimer's Disease (AD) or Vascular Dementia (VaD)).

Dosage:

Clinical trials mentioned doses of 0.2 mg (daily implied) and 0.4 mg twice daily in AD patients. Effects described as dose-dependent in both animal models (Aβ reduction, enzyme modulation) and human AD patients (cognition).

Study Quality Assessment:

Review article summarizing in vitro and in vivo studies, including specific animal models (APPswe/PS1, TgCRND8 mice) and cell cultures. Mentions clinical trials: one randomized clinical trial in VaD patients (using MMSE, ADL, CDR tests); one phase II multicenter, 3-arm randomized, double-blind, placebo-controlled trial in AD patients (evaluated as high methodological quality, using MMSE, ADAS-Cog, ADAS-nonCOG tests). Side effects (cholinergic system-related) mentioned as rare and mild at tested doses. Article is open access (CC BY license). Proteomic analysis mentioned as a method.

All Effects:

acetylcholinesterase inhibition amyloid-beta reduction cognitive improvement mitochondrial protection neuroinflammation neuroprotection

Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials (2016)

Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder (2015)

cocaine choice cocaine subjective effects pharmacokinetics +2 more

Authors:

Richard De La Garza II

Findings:

Huperzine A (HupA) was found to be safe and well-tolerated, with no serious adverse events or study discontinuations due to AEs. HupA did not significantly alter the pharmacokinetics of cocaine or its metabolites. Compared to placebo, the 0.4mg dose of HupA significantly attenuated several cocaine-induced subjective effects (e.g., "Any Drug Effect," "High," "Stimulated," "Willing to Pay," "Bad Effects") following 40mg IV cocaine and 20mg IV cocaine infusions, while the 0.8mg dose showed fewer significant effects. HupA did not significantly reduce the number of choices for cocaine infusions in a self-administration session.

Participants:

N=47 (Placebo n=16, HupA 0.4mg n=17, HupA 0.8mg n=14) individuals aged 18-55 years meeting DSM-5 criteria for cocaine use disorder, with recent cocaine-positive urine, experienced in smoked or intravenous cocaine use. Excluded for current psychiatric/medical illness, serious neurological/seizure disorder, psychoactive medication use, other drug/alcohol disorders (except nicotine). On average, participants were African American males, ~42 years old, using ~2g cocaine/day.

Dosage:

Huperzine A (HupA) or placebo administered orally twice daily (8:00 am, 6:00 pm) for 10 days with dose escalation. 0.4mg group: 0.2mg PM Day 1, 0.2mg BID Days 2-9, 0.2mg AM Day 10. 0.8mg group: 0.2mg PM Day 1, 0.2mg BID Days 2-5, 0.4mg BID Days 6-9, 0.4mg AM Day 10. Cocaine doses: 0 and 40mg IV (Days 1 & 9), 0 and 20mg IV (Day 10).

Study Quality Assessment:

Double-blind, placebo-controlled, between-groups study. Randomized. Sample size N=47 (14-17 per group). Used intravenous cocaine infusions (0, 20, 40mg), visual analogue scales (VAS) for subjective effects, cardiovascular monitoring (heart rate, blood pressure, ECG), pharmacokinetic (PK) analyses via liquid chromatography-tandem mass spectrometry. Statistical analysis used ANOVA and Holm-Sidak method for comparisons. Study approved by Institutional Review Boards (Baylor College of Medicine and MEDVAMC); informed consent obtained. Limitations acknowledged: multiple statistical tests (risk of Type I error), significant effects mainly at lower dose, modest effects confined to subjective measures, relatively small sample size per group.

All Effects:

cocaine choice cocaine subjective effects pharmacokinetics safety tolerability

Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (2013)

Alzheimer's disease activities of daily living cognitive function +2 more

Authors:

Guoyan Yang, Jian-Ping Liu, Jinzhou Tian, Yuyi Wang

Findings:

Compared with placebo, Huperzine A showed significant beneficial effects on cognitive function (measured by MMSE, HDS, WMS at various time points) and activities of daily living (measured by ADL at various time points), and one trial showed improvement in global clinical assessment (CDR). However, some trials using ADAS-Cog and ADCS-ADL found no significant differences. The authors conclude Huperzine A appears beneficial but findings should be interpreted with caution due to poor methodological quality of included trials. No severe adverse events were reported.

Participants:

Systematic review included 20 RCTs involving 1823 participants with Alzheimer's disease, aged between 50 to 85 years old.

Dosage:

The dosage of Huperzine A in the included trials varied from 0.2mg to 0.8 mg daily, with an average dose of about 0.37 mg daily. One trial reported tolerance at doses up to 0.4 mg BID (twice daily).

Study Quality Assessment:

Systematic review and meta-analysis of 20 Randomized Clinical Trials (RCTs). The methodological quality of most included trials was assessed as having a high risk of bias or being moderate/poor due to issues with reporting random sequence generation (75% unclear), allocation concealment (95% unclear/not reported), blinding (45% unclear/not reported), incomplete outcome data (most trials unclear), and selective outcome reporting (95% unclear). Potential publication bias was suggested by funnel plot asymmetry. Funding sources were disclosed and stated to have no role in the study.

All Effects:

Alzheimer's disease activities of daily living cognitive function global clinical assessment side effects

New insights into huperzine A for the treatment of Alzheimer's disease (2012)

AChE inhibition Alzheimer's disease treatment mechanism of action

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis (2009)

Alzheimer's disease activities of daily living cholinergic effects +2 more

Authors:

BS Wang, H Wang, HZ Chen, L Zhang, YY Song, ZH Wei

Findings:

Oral administration of HupA (300-500 microg daily for 8-24 weeks) led to significant improvements in MMSE and ADL scores in patients with AD. The effect size increased over treatment time. Most adverse events were cholinergic in nature, and no serious adverse events occurred, indicating HupA is well-tolerated.

Participants:

patients with AD (Alzheimer's disease)

Dosage:

Oral administration of 300-500 microg daily for 8-24 weeks.

Study Quality Assessment:

Meta-analysis based on four randomized clinical trials comparing huperzine A (HupA) with placebo. Primary outcome measures were mini-mental state examination (MMSE) and activities of daily living scale (ADL). Data analyzed using standard meta-analysis and meta-regression methods. Treatment duration was 8-24 weeks. Adverse events were monitored.

All Effects:

Alzheimer's disease activities of daily living cholinergic effects cognitive performance safety

A phase II trial of huperzine A in mild to moderate Alzheimer disease

ADAS-Cog Alzheimer's disease MMSE +2 more

Findings:

The primary analysis showed no significant cognitive effect (ADAS-Cog change at 16 weeks) for huperzine A 200 μg BID compared to placebo. Secondary analyses suggested potential cognitive benefit (ADAS-Cog and MMSE improvements) with the 400 μg BID dose, particularly at week 11 (ADAS-Cog p=0.001) and week 16 (MMSE p=0.007), though the ADAS-Cog effect at week 16 was not statistically significant (p=0.07). No significant effects were found on ADL, NPI, or CGIC at either dose. Huperzine A was generally well-tolerated.

Participants:

N=210 individuals with mild to moderate Alzheimer disease (AD), aged 50 years or older, with Mini-Mental State Examination (MMSE) scores between 10 and 24. Randomized to placebo (n=70), huperzine A 200 μg BID (n=70), or huperzine A 400 μg BID (n=70). 177 subjects completed the 16-week treatment phase.

Dosage:

Randomized to placebo, huperzine A 200 μg BID, or huperzine A 400 μg BID. Dose escalation schedule used: Group A started at 100 μg BID for 2 weeks, then 200 μg BID. Group B started at 100 μg BID for 2 weeks, then 200 μg BID for 2 weeks, then 300 μg BID for 2 weeks, then 400 μg BID.

Study Quality Assessment:

Phase II, multicenter, randomized, double-blind, placebo-controlled, 3-arm, dose-escalation trial (N=210). Duration: At least 16 weeks for primary analysis, up to 24 weeks total. Primary outcome: ADAS-Cog change at 16 weeks. Secondary outcomes: MMSE, ADCS-CGIC, ADCS-ADL, NPI. Used intention-to-treat analysis, LOCF imputation, mixed-effects modeling. Safety monitoring by Data and Safety Monitoring Board. Institutional review board approval and written informed consent obtained. Clinical trial identifier: NCT00083590. Power calculation performed (80% power for 3-point ADAS-Cog difference, deemed 'marginal statistical power'). Effectiveness of allocation concealment assessed. Funding: NIH/NIA and Neuro-Hitech, Inc. Classification of evidence: Class III evidence regarding the 200 μg BID dose.

All Effects:

ADAS-Cog Alzheimer's disease MMSE cognition tolerability

Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research

Alzheimer's disease acetylcholinesterase inhibition amyloid-beta reduction +4 more

Findings:

This review summarizes preclinical and clinical evidence for Huperzine A (HupA) as a neuroprotective agent for Alzheimer's disease (AD). HupA, an acetylcholinesterase inhibitor (AChEI), shows potential therapeutic benefits by modulating various molecular pathways, including reducing amyloid-β (Aβ) accumulation, promoting non-amyloidogenic APP processing, protecting mitochondria, regulating Fe2+ homeostasis, activating Wnt signaling, and reducing neuroinflammation. Some clinical trials suggest HupA improves cognition in AD and VaD patients, with reported dose and duration dependency, and is generally well-tolerated.

Participants:

The review discusses studies involving in vitro models (primary cortical neuron cultures, co-culture system of neural stem cells and microglia, primary astrocyte cultures), in vivo animal models (APPswe/PS1 mice, TgCRND8 mice, wild-type (WT) mice), and human subjects (patients with dementia including Alzheimer's disease (AD) or Vascular-associated Dementia (VaD)).

Dosage:

Mentions a small trial using 0.2 mg HupA tablets showing improvement in 58% of AD patients. A phase II trial showed cognitive enhancement with 0.4 mg HupA twice a day, tolerated for 24 weeks. Effects are described as dose-dependent (Aβ reduction in mice) and dose/duration-dependent (cognition in AD patients). Side effects noted at 'high doses'.

Study Quality Assessment:

The text describes a review summarizing findings from various studies. It mentions specific preclinical methods (e.g., proteomic analysis, specific mouse models like APPswe/PS1). For human studies, it references measurement tools (MMSE, ADAS-Cog, ADL, etc.), mentions a 'randomized clinical trial' for VaD, a 'small trial' for AD, and a 'phase II multicenter, 3-arm randomized, double-blind placebo-controlled trial' evaluated as having 'high methodological quality'. Study durations (8 weeks, 24 weeks) and side effects/tolerability are noted. Funding source (ANID grant) and conflict of interest statement (none declared) are mentioned for the review itself.

All Effects:

Alzheimer's disease acetylcholinesterase inhibition amyloid-beta reduction anti-inflammatory cognition mitochondrial protection neuroprotection

Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials

activities of daily living adverse events cognitive function +1 more

Findings:

Huperzine A appeared to show beneficial effects compared to placebo on cognitive function (measured by MMSE, HDS, WMS at various time points), activities of daily living (measured by ADL at various time points), and global clinical assessment (measured by CDR in one trial). However, one trial found no significant change on ADAS-Cog or ADCS-ADL. No severe adverse events were reported, and common side effects were mild (e.g., nausea, anorexia, dizziness). The authors conclude that findings should be interpreted with caution due to the poor methodological quality of the included trials.

Participants:

Systematic review included 20 RCTs involving 1823 participants with Alzheimer's disease, aged between 50 to 85 years old.

Dosage:

Dosage in included trials varied from 0.2mg to 0.8 mg daily (average ~0.37 mg daily). One trial reported tolerance up to 0.4 mg BID (twice daily).

Study Quality Assessment:

Systematic review and meta-analysis of 20 Randomized Clinical Trials (RCTs). Methodological quality assessment using Cochrane risk of bias tool found the general quality of most included trials was moderate or poor ('high risk of bias'). Specific issues noted: inadequate reporting of random sequence generation (75% unclear), allocation concealment (95% unclear), blinding (45% unclear), incomplete outcome data/attrition (most unclear), and selective outcome reporting (95% unclear). Potential publication bias suggested by asymmetrical funnel plots. Limitations acknowledged: poor methodological quality of included trials, different measurement scales used, varied treatment durations, diverse reporting methods, short treatment duration in most trials (8-12 weeks).

All Effects:

activities of daily living adverse events cognitive function global clinical assessment

We value your privacy

Categories & Effectiveness

Brain Health

Acetylcholine Support

Neuro-Repair Support

Brain Antioxidant Shield

Cognition

Memory & Recall

Mental Acuity

Systemic Health

Cellular Anti-Aging

Dosage & Side Effects

Recommended Dosage

Potential Side Effects

Bioavailability & Half-Life

Interactions & Stacks

Benefits by Use Case

Memory Support (esp. Age-Related)

Alzheimer's/Dementia Adjunct

Focus & Attention

Mechanism of Action

Frequently Asked Questions

Summary & Expert Opinion

Research Studies

Natural products: Potential therapeutic agents to prevent skeletal muscle atrophy (2022)

Authors:

Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease (2021)

Authors:

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials (2016)

Authors:

Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder (2015)

Authors:

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (2013)

Authors:

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

New insights into huperzine A for the treatment of Alzheimer's disease (2012)

Findings:

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis (2009)

Authors:

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

A phase II trial of huperzine A in mild to moderate Alzheimer disease

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials

Findings:

Participants:

Dosage:

Study Quality Assessment:

All Effects:

Similar Nootropics

Berberine

Holy Basil

L-Theanine